Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: A matched case-control study

Journal of Gastroenterology

Volumn 46, Issue 11, 2011, Pages 1335-1343

  Hiramatsu, Naoki ^a   Inoue, Yuko ^a   Oze, Tsugiko ^a   Kurashige, Nao ^a   Yakushijin, Takayuki ^a   Mochizuki, Kiyoshi ^a   Miyagi, Takuya ^a   Tatsumi, Tomohide ^a   Kiso, Shinichi ^a   Kanto, Tatsuya ^a   Kasahara, Akinori ^a   Takehara, Tetsuo ^a   Oshita, Masahide ^b   Mita, Eiji ^c   Hagiwara, Hideki ^d   Inui, Yoshiaki ^e   Katayama, Kazuhiro ^f   Tamura, Shinji ^g   Yoshihara, Harumasa ^h   Imai, Yasuharu ⁱ   Hayashi, Norio ^d   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e Hyogo Prefectural Nishinomiya Hospital   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g Minoh City Hospital   (Japan)

^h OSAKA ROSAI HOSPITAL   (Japan)

ⁱ Ikeda Municipal Hospital   (Japan)

Author keywords

Hepatitis C virus; Matched case control study; Normal alanine aminotransferase; Pegylated interferon plus ribavirin combination therapy; Propensity score method

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROPENSITY SCORE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84655169255     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0455-1     Document Type: Article

References (24)

1. M Martinot-Peignoux N Boyer D Cazals-Hatem BN Pham A Gervais V Le Breton 2001 Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA Hepatology 34 1000 1005 (Pubitemid 33032035)
2. T Okanoue A Makiyama M Nakayama Y Sumida H Mitsuyoshi T Nakajima 2005 A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase J Hepatol 43 599 605 (Pubitemid 41253226)
3. M Persico E Persico R Suozzo S Conte M De Seta L Coppola 2000 Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels Gastroenterology 118 760 764 (Pubitemid 30171625)
4. C Puoti R Castellacci F Montagnese S Zaltron G Stornaiuolo N Bergami 2002 Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC) J Hepatol 37 117 123 (Pubitemid 34713063)
5. K Tsuji K Yamasaki M Yamanishi M Kawakami S Shirahama 2001 Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study J Gastroenterol Hepatol 16 536 540 (Pubitemid 34188861)
6. A Sangiovanni R Morales G Spinzi M Rumi A Casiraghi R Ceriani 1998 Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study Hepatology 27 853 856 (Pubitemid 28103565)
7. L Serfaty O Chazouilleres JM Pawlotsky T Andreani C Pellet R Poupon 1996 Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity Gastroenterology 110 291 295 (Pubitemid 26021631)
8. ML Shiffman CA Stewart CM Hofmann MJ Contos VA Luketic RK Sterling 2000 Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy J Infect Dis 182 1595 1601
9. NC Tassopoulos 1999 Treatment of patients with chronic hepatitis C and normal ALT levels J Hepatol 31 Suppl 1 193 196 (Pubitemid 30002717)
10. S Zeuzem M Diago E Gane KR Reddy P Pockros D Prati 2004 Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 127 1724 1732 (Pubitemid 39575851)
11. MG Ghany DB Strader DL Thomas LB Seeff 2009 Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 1335 1374
12. CF Gholson K Morgan G Catinis D Favrot B Taylor E Gonzalez 1997 Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study Am J Gastroenterol 92 1788 1792 (Pubitemid 27440891)
13. S Herve G Savoye G Riachi MF Hellot O Goria E Lerebours 2001 Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 13 495 500 (Pubitemid 32466250)
14. C Puoti L Bellis A Galossi R Guarisco S Nicodemo L Spilabotti 2008 Antiviral treatment of HCV carriers with persistently normal ALT levels Mini Rev Med Chem 8 150 152 (Pubitemid 351320938)
15. C Puoti L Bellis F Martellino R Guarisco O Dell' Unto L Durola 2005 Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test J Hepatol 43 534 535 (Pubitemid 41111437)
16. C Puoti R Castellacci F Montagnese 2000 Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 32 634 643
17. C Puoti A Magrini T Stati P Rigato F Montagnese P Rossi 1997 Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels Hepatology 26 1393 1398 (Pubitemid 27520001)
18. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982
19. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355
20. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 (Pubitemid 32913521)
21. C Puoti AM Pellicelli M Romano F Mecenate R Guarisco G Barbarini 2009 Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study Liver Int 29 1479 1484
22. S Deuffic-Burban G Babany I Lonjon-Domanec P Deltenre V Canva-Delcambre S Dharancy 2009 Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France Hepatology 50 1351 1359
23. P Bedossa T Poynard 1996 An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group Hepatology 24 289 293 (Pubitemid 26260021)
24. T Okanoue Y Itoh M Minami H Hashimoto K Yasui H Yotsuyanagi 2008 Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts Hepatol Res 38 27 36 (Pubitemid 350182574)